Table 4.

Summary of clinical endpoints according to cancer type and CGA-results at baseline (before chemotherapy).

	(Neo)adjuvant chemotherapy for solid malignancies (n = 72)	Palliative chemotherapy for solid malignancies (n = 49)	Indolent haematological malignancies (n = 115)	Aggressive haematological malignancies (n = 55)
Progressive disease and/or decline of IADL-independence (≥2 points) 1 year after chemotherapy (primary endpoint)	27/72 (37.5%)	35/49 (71.4%)	42/115 (36.5%)	22/55 (40%)
Unknown	9/72 (12.5%)	4/49 (8.2%)	9/115 (7.8%)	3/55 (5.5%)
Abnormal G8-score	22/27 (81.5%)	22/35 (62.9%)	35/42 (83.3%)	17/22 (77.3%)
Fit	4/27 (14.8%)	4/35 (11/4%)	5/42 (11.9%)	2/22 (9.1%)
Vulnerable	11/27 (40.7%)	19/35 (54.3%)	18/42 (42.9%)	7/22 (31.8%)
Frail	12/27 (44.4%)	12/35 (34.3%)	19/42 (45.2%)	13/22 (59.1%)
Median OS in months (IQR)	44.5 (22-59)	18 (12-29.5)	34 (20-54)	35 (16-52)
Unknown	0	0	0	0
Abnormal G8-score	41 (13.5-60.5)	13 (10.5-32.5)	34 (18-52.5)	35.5 (16.3-51)
Fit	47.5 (20.3-63)	19 (9-26)	48 (21.3-59.8)	48 (35-62)
Vulnerable	47.5 (20.3-63)	15.5 (12-23.8)	35 (23.5-51.3)	34 (17.5-51.5)
Frail	39.5 (11.5-57.8)	23.5 (12.5-38.3)	33 (14-54)	30 (8.5-51)
Preterm termination of chemotherapy	29/72 (40.3%)	26/49 (53.1%)	48/115 (41.7%)	16/55 (29.1%)
Unknown	0	0	0	0
Abnormal G8-score	21/29 (72.4%)	15/26 (57.7%)	33/48 (68.8%)	15/16 (93.8%)
Fit	6/29 (20.7%)	4/26 (15.4%)	5/48 (10.4%)	1/16 (6.3%)
Vulnerable	17/29 (58.6%)	13/26 (50%)	17/48 (35.4%)	4/16 (25%)
Frail	6/29 (20.7%)	9/26 (34.6%)	26/48 (54.2%)	11/16 (68.8%)
Deceased within 1 year after chemotherapy	9/72 (12.5%)	12/49 (24.5%)	16/115 (13.9%)	12/55 (21.8%)
Unknown	0	0	0	0
Abnormal G8-score	8/9 (88.9%)	7/12 (58.3%)	12/16 (75%)	9/12 (75%)
Fit	1/9 (11.1%)	2/12 (16.7%)	2/16 (12.5%)	1/12 (8.3%)
Vulnerable	4/9 (44.4%)	6/12 (50%)	5/16 (31.3%)	3/12 (25%)
Frail	4/9 (44.4%)	4/12 (33.3%)	9/16 (56.3%)	8/12 (66.7%)